|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||56.85 - 57.27|
|52 Week Range||53.82 - 117.54|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.48%|
Merck’s (MRK) immunology products include Simponi and Remicade. Its cardiovascular products include Zetia, Vytorin, Adempas, and Atozet.
The non-farm payrolls for March rose by 103,000, which was below the consensus expectation of 193,000 jobs being added and way below the February number of 326,000 jobs. The unemployment rate for March remained unchanged at 4.1%.
BlackRock announces that the iShares Board of Trustees and Board of Directors have authorized a share split for iShares Global 100 ETF , iShares Global Healthcare ETF , iShares Global Consumer Staples ETF and iShares MSCI EM ESG Optimized ETF .
In his first State of the Union speech, President Trump didn’t have any surprises for the markets (SPY). At the annual State of the Union meeting, President Trump addressed a joint session of Congress. President Trump stayed away from any surprise statements that could have spooked the markets.
In 1928, Congress passed a joint resolution establishing Child Health Day, the express purpose of which was to raise awareness “of the fundamental necessity of a year-round program to protect and develop ...
Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.
The Cardiovascular and Metabolic Disease (or CVMD segment) contributed ~35.1% of total revenues for AstraZeneca (AZN) in 2Q17.
Bristol-Myers Squibb (BMY) surpassed Wall Street analysts’ estimate for 2Q17 revenues, reporting $5.14 billion compared to the estimate of $5.09 billion.
AstraZeneca (AZN) is one of the largest pharmaceutical companies by revenue. The company operates in over 100 countries and deals with primary care and specialty care medicines.
As discussed earlier, Johnson & Johnson’s (JNJ) 2Q17 performance was positive across all three of its segments. Let’s look at major developments for the company in 2Q17. On July 13,…
Allergan's International segment reported revenues of $737.3 million for 1Q17, which was 9.5% higher than the $673.3 million it reported in 1Q16.